Research progress on the role of cholesterol in hepatocellular carcinoma
European Journal of Pharmacology, ISSN: 0014-2999, Vol: 938, Page: 175410
2023
- 9Citations
- 13Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations9
- Citation Indexes9
- CrossRef4
- Captures13
- Readers13
- 13
Review Description
Hepatocellular carcinoma (HCC) is often diagnosed at advanced stages with no effective treatment options. Mechanistically, it is a complex biological process. Recently, the main cause of its incidence is changing from viral to non-viral. It has been shown that high cholesterol levels can cause the further transformation of non-alcoholic fatty liver disease (NAFLD) to HCC, but some investigations have found that serum cholesterol levels are negatively correlated with morbidity and mortality. Conflicting experimental results and epidemiological investigations illustrate the complex mechanisms of HCC. Cholesterol is essential for the survival of the body and tumors, although research on the function of cholesterol in tumors is evolving, the use of lowering cholesterol drugs in treating HCC remains limited. In this review, the cholesterol-involved mechanisms that cause the development of HCC or reduce the mortality and the latest progress in the use of cholesterol in the treatment of HCC and prospects for prevention and diagnosis have been summarized.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0014299922006719; http://dx.doi.org/10.1016/j.ejphar.2022.175410; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85143162138&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36511324; https://linkinghub.elsevier.com/retrieve/pii/S0014299922006719; https://dx.doi.org/10.1016/j.ejphar.2022.175410
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know